Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Promising multi-strain HIV vaccine candidate emerges


AIDS researchers have developed a candidate vaccine strategy that, for the first time, demonstrates an ability to elicit antibodies that block the infection of multiple HIV virus strains -- an elusive scientific goal that has been pursued for a decade.

The candidate vaccine - still early in developmental stages at the Institute of Human Virology (IHV) -- is described in a report to appear during the week of Aug. 19-23 in the U.S. Proceedings in the National Academy of Sciences (PNAS). It is authored by Drs. Timothy Fouts, Anthony Devico, and colleagues at the IHV, a center of the University of Maryland Biotechnology Institute and affiliated with the University of Maryland Medical Center, and Dr. Ranajit Pal and colleagues at Advanced BioScience Laboratories, Inc. (ABL) in Kensington, Md.

One of the major challenges in developing an effective AIDS vaccine has long been the fact that the virus that causes AIDS, much like the influenza virus, exists as multiple strains that present many different faces to the immune system, say the authors. The surface of the AIDS virus, HIV, is coated with a protein called gp120 that has chemical features that vary from strain to strain. It has been difficult for researchers to find a single vaccine component that is able to generate antibodies that recognize the many forms of gp120 that exist in nature.

The IHV/ABL research team approached the problem by recognizing that all gp120 molecules have a shared characteristic that allows all HIV strains to bind a molecule on human target cells called CD4. Importantly, once gp120 forms a complex with CD4, it undergoes structural and chemical changes that reveal features shared by all HIV strains.

Taking advantage of this knowledge, the team produced artificial gp120-CD4 complexes that were chemically treated in order to glue or "crosslink" them together. The complexes were then used to generate antibodies in small animals and monkeys.

"The gp120-CD4 complex has shown a consistent ability to generate antibodies that neutralize a wide range of HIV-1 isolates," says Dr. Devico, assistant professor, IHV. "The preliminary findings indicate the gp120-CD4 complex might serve as a useful model for HIV vaccine development," he adds.

Long the hope of AIDS researchers, it now appears that developing a single HIV vaccine for multiple viruses is indeed an increasingly realistic endeavor, according to IHV Director Dr. Robert C. Gallo.

"This is one of the more exciting findings that I have witnessed in HIV/AIDS research since the early days when it seemed scientific advances were announced regularly," says Dr. Gallo, who is also co-discover of the AIDS virus.

"From the beginning of the field of HIV/AIDS research, the most important goal was to develop a vaccine that prevents virus infection," says Dr. Gallo. "The difficulties have been many, spanning close to two decades. But this has the potential to bring us a major step forward in that ultimate quest. At the Institute of Human Virology, we will make this our prime effort."

The timing couldn’t be more critical, he says.

"HIV/AIDS has overcome the 1918 influenza pandemic and bubonic plague of the 14th century to become the worst epidemic and deadliest disease in medical history," comments Dr. George Lewis, director of the IHV’s Division of Vaccine Development. "Twenty-five million persons have died worldwide, another 40 million are infected and the numbers are rapidly escalating second to second, he explains.

"While advances in therapeutics are helping many with the disease live longer and healthier lives," Lewis adds, "most of the world lacks theses resources and our best bet to stop the AIDS epidemic is a vaccine. We hope this will become an effective tool toward that global goal."

Though designed as a preventative vaccine, the complex might also be useful as a therapeutic vaccine, say the authors. The gp120-CD4 complex will continue to be evaluated with regard to safety and immunogenicity within the next two years should precede into Phase I clinical trials, according to Dr. Gallo.

Gwen Fariss Newman | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Inflammation Triggers Unsustainable Immune Response to Chronic Viral Infection
24.10.2016 | Universität Basel

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

New method increases energy density in lithium batteries

24.10.2016 | Power and Electrical Engineering

International team discovers novel Alzheimer's disease risk gene among Icelanders

24.10.2016 | Life Sciences

New bacteria groups, and stunning diversity, discovered underground

24.10.2016 | Life Sciences

More VideoLinks >>>